From a therapeutic point of view, they represent attractive drugable targets in clinical routine, as IDH inhibitors (e.g., ivosidenib for IDH1 mutations and enasidenib for IDH2 mutations) have been introduced for patients with relapsed or refractory AML (r/r AML) and/or elderly/frail AML patients as firstline therapy harboring IDH mutations with promising results regarding response and survival [25–27]. Here, IDH2 is linked to acute myeloid leukemia.